Scarica l'app Stockscreener
13.75
0.07%
-0.010
Pre-mercato:
13.74
-0.010
-0.07%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Organon Co Borsa (OGN) Ultime notizie
Organon & Co. (OGN) Stock Forecasts - Yahoo Finance
Sun Pharma to raise Rs 10,000 crore to part-finance Organon deal - The Economic Times
Organon & Co Says It Does Not Expect To Record Milestone Expense In Q3 2026 - TradingView
Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing - Business Wire
Organon & Co. (OGN) Stock Forecasts - Yahoo! Finance Canada
Organon reports six‑year MIUDELLA data as FDA reviews longer use - Mugglehead Investment Magazine
Organon & CoFDA Accepts Snda for Miudella - Moomoo
Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting - Business Wire
Organon & Co. (OGN) Stock Forecasts - Yahoo Finance
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - Zacks Investment Research
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - Yahoo Finance
USU6836GAB42 Bond Yield and Price — BONDSCOM:USU6836GAB42 - TradingView
Organon & Co. (OGN) Stock Forecasts - Yahoo! Finance Canada
Organon & Co. (OGN) Stock Forecasts - Yahoo! Finance Canada
Organon & Co. (OGN) Stock Forecasts - Yahoo Finance
Organon & Co stock hits 52-week high at 13.79 USD - Investing.com
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock - Zacks Investment Research
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock - Yahoo Finance
Organon presents VTAMA analysis: Organon stock gains 1.16 percent - AD HOC NEWS
Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference - Business Wire
Organon & Co. (OGN) Stock Forecasts - Yahoo Finance
Tangible book value per share of Organon & Co. – HAN:7XP - TradingView
Organon & Co. Revenue Breakdown – HAN:7XP - TradingView
Sun Pharma plans $1 billion local debt sale for loan takeout, sources say - ETPharma.com
Sun Pharma plans $1 billion rupee debt sale to refinance Organon acquisition loan - Firstpost
Organon & Co. (OGN) Stock Forecasts - Yahoo! Finance Canada
Organon & Co. (OGN) Stock forecasts - Yahoo Finance Singapore
Organon & Co. (OGN) Stock Forecasts - Yahoo Finance
Precision Trading with Organon & Co. (OGN) Risk Zones - Stock Traders Daily
Why Organon (OGN) Is Getting Attention Today - Yahoo Finance
Organon (OGN) Wins FDA Review Acceptance For Its Hormone Free Contraceptive Device - Yahoo Finance
Is Trending Stock Organon & Co. (OGN) a Buy Now? - Yahoo Finance
Class A Dig — Organon/Sun Pharma premature-close (May ACQ deleted; early-2027 expected) - Dealroom
how InvestingPro spotted Organon’s 65% gain in healthcare sector By Investing.com - Investing.com
Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA - Business Wire
Organon Says Application to Extend Miudella IUD Use to Six Years Accepted by FDA for Review - Yahoo Finance
Responsive Playbooks and the OGN Inflection - Stock Traders Daily
Organon Stock: A Merger-Arbitrage Hold With Limited Upside (NYSE:OGN) - Seeking Alpha
Sun Pharma Gets Investment-Grade Ratings From Moody's, S&P for USD 11.75 Bn Organon Deal - Medical Dialogues
Sun Pharma gets ratings boost from Moody's, S&P over $11.75-bn Organon bid - Business Standard
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Sun Pharma receives ratings boost over USD 11.75-billion Organon acqui - Daily Pioneer
Sun Pharma Gets Ratings Boost From Moody's, S&P Over $11.75-Bn Organon & Co Acquisition Bid - outlookbusiness.com
Sun Pharma gets ratings boost from Moody's, S&P over ₹11.75-billion Organon & Co acquisition bid - BusinessLine
Sun Pharma gets ratings boost from Moody's, S&P over $11.75-bn Organon bid - pharma.economictimes.indiatimes.com
Sun Pharma gets ratings boost from Moody's, S&P over $11.75 bn Organon & Co acquisition bid - ET Manufacturing
Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bid - The Economic Times
Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bid - The Economic Times
Sun Pharma Gets Ratings Boost After Organon Acquisition Bid - Rediff MoneyWiz
Organon & Co stock hits 52-week high at $13.78 By Investing.com - Investing.com Nigeria
0.53%
0.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):